CryoLife announced that it was renaming and rebranding itself to Artivion, effective immediately. Derived from the words “aorta”, “innovation”, and “vision”, the company’s new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease, a press release details.
In conjunction with these changes, effective 24 January 2022, the company will also change its ticker symbol on the New York Stock Exchange to “AORT” from “CRY.”
“Through a combination of legacy products and strategic acquisitions and divestitures over the last five years, we have transformed from a tissue and adhesives focused company to one with a premier portfolio of aortic products,” said Pat Mackin, chairman, president and chief executive officer of Artivion.
“Today marks an important milestone for our company. We look forward to embarking on our next chapter as a leader in developing simple, elegant solutions to address cardiac and vascular surgeons’ most difficult clinical challenges in treating patients with aortic disease.”
Artivion will discuss its business, its strategy, and the rebrand at an Investor & Analyst Day on 23 March 2022, in New York City, the press release advises. Details of the event will be provided at a later date.
